Olaparib Quantification in Human Plasma for Clinical Purposes using High-Performance Liquid Chromatography with UV detector

被引:4
作者
Nalanda, Revu Baby [1 ]
Rao, Atla [1 ]
Sankar, Dannana Gowri [2 ]
机构
[1] Andhra Univ, Shri Vishnu Coll Pharm, Dept Pharmaceut Anal & Qual Assurance, Visakhapatnam, Andhra Pradesh, India
[2] Andhra Univ, Coll Pharmaceut Sci, Dept Pharmaceut Anal & Qual Assurance, Visakhapatnam, Andhra Pradesh, India
关键词
Olaparib; HPLC; Human plasma; Isocratic; Liquid-liquid extraction; PARP INHIBITOR OLAPARIB; OVARIAN-CANCER; BREAST-CANCER; PHASE-I; PHARMACOKINETICS; VALIDATION; POLYMERASE; THERAPY; ASSAY;
D O I
10.1080/22297928.2019.1650109
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A simple, sensitive and accurate HPLC-UV detection method for the determination of olaparib in human plasma samples was developed. Separation was successfully achieved using an YMC C18 reverse phase column (250 x 4.6 mm i.d.; 5 & mu;m) under isocratic mobile phase conditions consisting of methanol-0.1 % orthophosphoric acid (60:40, v/v) and ultra-violet detection was achieved at 220 nm. Extraction of the target compounds was completed using liquid-liquid extraction technique. No endogenous substances were found to interfere with the peaks of drug and internal standard. Good linearity (r(2) > 0.99) was achieved for the concentration range of 100-5000 ng/mL and detection limit was 20 ng/mL. The Intra and Inter-day precision and accuracy were found to be within acceptable limits (<15 %). The overall recovery for olaparib was found to be 50.44 %. Stability data revealed that the drug was stable in plasma under various test conditions. Matrix effects were not observed. The present method was effectively implemented to determine the concentration of olaparib in human plasma.
引用
收藏
页码:526 / 534
页数:9
相关论文
共 22 条
[1]   Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery [J].
Bundred, Nigel ;
Gardovskis, Janis ;
Jaskiewicz, Janusz ;
Eglitis, Janis ;
Paramonov, Viktor ;
McCormack, Peter ;
Swaisland, Helen ;
Cavallin, Maria ;
Parry, Tony ;
Carmichael, James ;
Dixon, J. Michael .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) :949-958
[2]   Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells [J].
Daumar, Pierre ;
Dufour, Robin ;
Dubois, Clemence ;
Penault-Llorca, Frederique ;
Bamdad, Mahchid ;
Mounetou, Emmanuelle .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2018, 152 :74-80
[3]   PARP inhibitors in ovarian cancer: evidence, experience and clinical potential [J].
Evans, Tarra ;
Matulonis, Ursula .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (04) :253-267
[4]   Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].
Fong, Peter C. ;
Boss, David S. ;
Yap, Timothy A. ;
Tutt, Andrew ;
Wu, Peijun ;
Mergui-Roelvink, Marja ;
Mortimer, Peter ;
Swaisland, Helen ;
Lau, Alan ;
O'Connor, Mark J. ;
Ashworth, Alan ;
Carmichael, James ;
Kaye, Stan B. ;
Schellens, Jan H. M. ;
de Bono, Johann S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134
[5]  
Jung-min L., 2013, J CLIN ONCOL, V31, P2514
[6]   Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation [J].
Kaufman, Bella ;
Shapira-Frommer, Ronnie ;
Schmutzler, Rita K. ;
Audeh, M. William ;
Friedlander, Michael ;
Balmana, Judith ;
Mitchell, Gillian ;
Fried, Georgeta ;
Stemmer, Salomon M. ;
Hubert, Ayala ;
Rosengarten, Ora ;
Steiner, Mariana ;
Loman, Niklas ;
Bowen, Karin ;
Fielding, Anitra ;
Domchek, Susan M. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) :244-250
[7]   Treatment options in recurrent ovarian cancer: latest evidence and clinical potential [J].
Luvero, Daniela ;
Milani, Andrea ;
Ledermann, Jonathan A. .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (05) :229-239
[8]   DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer [J].
Mateo, J. ;
Carreira, S. ;
Sandhu, S. ;
Miranda, S. ;
Mossop, H. ;
Perez-Lopez, R. ;
Rodrigues, D. Nava ;
Robinson, D. ;
Omlin, A. ;
Tunariu, N. ;
Boysen, G. ;
Porta, N. ;
Flohr, P. ;
Gillman, A. ;
Figueiredo, I. ;
Paulding, C. ;
Seed, G. ;
Jain, S. ;
Ralph, C. ;
Protheroe, A. ;
Hussain, S. ;
Jones, R. ;
Elliott, T. ;
McGovern, U. ;
Bianchini, D. ;
Goodall, J. ;
Zafeiriou, Z. ;
Williamson, C. T. ;
Ferraldeschi, R. ;
Riisnaes, R. ;
Ebbs, B. ;
Fowler, G. ;
Roda, D. ;
Yuan, W. ;
Wu, Y. -M. ;
Cao, X. ;
Brough, R. ;
Pemberton, H. ;
A'Hern, R. ;
Swain, A. ;
Kunju, L. P. ;
Eeles, R. ;
Attard, G. ;
Lord, C. J. ;
Ashworth, A. ;
Rubin, M. A. ;
Knudsen, K. E. ;
Feng, F. Y. ;
Chinnaiyan, A. M. ;
Hall, E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (18) :1697-1708
[9]  
Miller RE, 2016, CLIN ADV HEMATOL ONC, V14, P619
[10]   Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer [J].
Moore, Kathleen N. ;
Monk, Bradley J. .
ONCOLOGIST, 2016, 21 (08) :954-963